Geron Corporation (NASDAQ:GERN) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Geron Corporation has received an average rating of "Hold" from seven brokerage firms, with one sell, three hold, and three buy recommendations.
• The stock's average twelve-month target price is $3.7857, while Goldman Sachs set a lower price objective of $1.00 with a sell rating.
• Geron reported a 5455.6% year-over-year increase in revenue for the last quarter, totaling $49.04 million, exceeding analyst expectations.

Geron Corporation (NASDAQ:GERN - Get Free Report) has been assigned an average recommendation of "Hold" from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $3.7857.

Separately, The Goldman Sachs Group started coverage on Geron in a report on Thursday, July 10th. They set a "sell" rating and a $1.00 price objective on the stock.

Geron Trading Up 1.6%

NASDAQ:GERN opened at $1.29 on Friday. Geron has a fifty-two week low of $1.09 and a fifty-two week high of $4.65. The company has a debt-to-equity ratio of 0.46, a current ratio of 7.87 and a quick ratio of 6.79. The stock has a market capitalization of $823.05 million, a PE ratio of -9.92 and a beta of 0.63. The business's 50-day simple moving average is $1.33 and its 200-day simple moving average is $1.40.

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The business had revenue of $49.04 million for the quarter, compared to analysts' expectations of $47.30 million. During the same quarter in the previous year, the business posted ($0.10) EPS. Geron's revenue for the quarter was up 5455.6% on a year-over-year basis. Sell-side analysts expect that Geron will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Geron

Several institutional investors have recently modified their holdings of GERN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Geron by 2.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company's stock valued at $627,000 after buying an additional 8,123 shares during the last quarter. Frisch Financial Group Inc. increased its position in shares of Geron by 84.3% during the 1st quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 8,700 shares during the last quarter. E Fund Management Co. Ltd. increased its position in shares of Geron by 12.0% during the 2nd quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company's stock worth $130,000 after purchasing an additional 9,849 shares during the last quarter. Savant Capital LLC increased its position in shares of Geron by 73.8% during the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 11,074 shares during the last quarter. Finally, 111 Capital acquired a new position in shares of Geron during the 4th quarter worth approximately $52,000. Institutional investors own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.